Canine C-peptide for characterization of experimental diabetes in dogs.
Radioimmunoassay of canine C-peptide (CCP) was developed for the characterization of endogenous beta cell function in experimentally diabetic dogs. The animals were rendered diabetic by subtotal pancreatectomy and intrasurgical infusion of 2 mg kg-1 streptozotocin into the superior pancreaticoduodenal artery. After an average duration of diabetes of 5 months the animals showed zero peripheral venous fasting CCP levels with no response to feeding, OGTT/i.v. glucagon loading or i.v. glucose tolerance testing. The data on CCP levels were entirely coincident with simultaneously measured plasma IRI levels. In non-diabetic control animals there were clear-cut CCP increases after all stimuli. The experimental model provided an IDDM-type diabetes without toxic symptoms but with sufficient exocrine pancreatic function. The comparison showed that plasma IRI analyses would also allow a reliable characterization of insulinogenic functions in these animals.
D000818:Animals; D001786:Blood Glucose / Q000032:analysis*; D002096:C-Peptide / Q000032:analysis*; D003921:Diabetes Mellitus, Experimental / Q000097:blood* / Q000503:physiopathology; D004285:Dogs; D005260:Female; D005951:Glucose Tolerance Test; D007328:Insulin / Q000097:blood*; D007515:Islets of Langerhans / Q000503:physiopathology; D008297:Male; D011863:Radioimmunoassay
D001786:Blood Glucose; D002096:C-Peptide; D007328:Insulin